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Abstract: A series of pyrazolo[3,4-d]pyrimidine derivatives was synthesized and evaluated for the Src 
kinase inhibitory activities. Compound 6e and 10c exhibited inhibition of Src kinase with an IC50 value of 
5.6 and 5.1 µM, respectively. Hydroxamate derivative 15a was found to be a metal-mediated inhibitor for 
human Csk with an IC50 value of 2.0 µM showing 56-fold selectivity over Src kinase inhibition. 
 
 
Introduction  
 
The Src family of tyrosine kinases (SFKs) is 
comprised of nine tyrosine kinases viz. Src, 
Lck, Fyn, Yes, Hck, Blk, Fgr, Lyn and Yrk. 
SFKs have important role in signaling 
pathways that control a diverse spectrum of 
biological activities, such as cell division, 
growth factor signaling, differentiation, 
survival, adhesion, migration, and invasion.1 
Src tyrosine kinase expression is frequently 
elevated in a number of tumors including 
colon, breast, prostate, lung, ovary, and 
pancreas compared with the adjacent normal 
tissues. Src kinase is a key modulator of 
cancer cell invasion and metastasis.2 Src also 
plays a crucial role in osteoclast function 
where key function of the enzyme is to  
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promote the rapid assembly and disassembly 
of the podosomes, and regulation of vesicle 
transport and secretion of proteases.3 Thus, 
Src has become an attractive therapeutic 
target for the design of new therapeutic 
agents.4 A number of Src kinase inhibitors 
have shown potential as both anti-
proliferative and anti-invasive agents in 
preclinical studies in different solid tumors.5 
Pheylpyrazolopyrimidine derivatives (PP1 
and PP2) (Figure 1) have been reported as 
SFK inhibitors.6 We evaluated a series of 3-
phenylpyrazolopyrimidine derivatives and 
1,4-disubstituted triazoles for their c-Src 
kinase inhibitory activity.7 
In continuation of our efforts towards the 
development of c-Src kinase inhibitors,8 
herein we describe synthesis of novel 
pyrazolo[3,4-d]pyrimidine derivatives by 
structural modification of pyrazolo[3,4-
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d]pyrimidine scaffold (Figure 1) and 
evaluation of their Src tyrosine kinase 
inhibitory activity. The purpose of this study 
was to establish the structure-activity 
relationship to optimize pyrazolo[3,4-
d]pyrimidine derivatives as potential Src 
kinase inhibitors. 
 
Figure 1. Pyrazolo[3,4-d]pyrimidine 
scaffold, PP1, and PP2 as Src kinase 
inhibitors. 
 
Results and Discussion 
 
Chemistry. The synthesis of N1-substituted 
3-phenylpyrazolo[3,4-d]pyrimidine 
derivatives (6a-e) was accomplished by 
sequence of reactions as shown in Scheme 1. 
Reaction of benzoyl chloride (1) with 
malononitrile (2) in the presence of sodium 
hydride in THF gave benzoylmalononitrile 
(3), which on methylation with 
dimethylsulfate (DMS, Me2SO4) in the 
presence of NaHCO3 in dioxane afforded 2-
(methoxyphenylmethylene)malononitrile 
(4). Reaction of 4 with different hydrazines 
viz. NH2NH2.HCl, tert-butylhydrazine, 2-
azidoethyl hydrazine, 2-hydroxyethyl 
hydrazine, and cyclohexyl hydrazine in the 
presence of triethylamine (Et3N) afforded 
corresponding 5-amino-3-phenyl-pyrazolo-
4-carbonitriles (5a-e). Reaction of 5a-e with 
formamide at 180 ºC for 24 h afforded 
pyrazolopyrimidines (6a-e). 
 
Scheme 1. Synthesis of N1-substituted 
3-phenylpyrazolo[3,4-d]pyrimidine 
derivatives. 
N1-Carboxylic acid ester pyrazolo[3,4-
d]pyrimidine derivatives (7a-f) were 
synthesized from the reaction of 3-phenyl-
1H-pyrazolo[3,4-d]pyrimidine-4-ylamine 
(6a) with ethyl 2-bromoacetate, ethyl 3-
bromopropionate, ethyl 4-bromobutyrate, 
ethyl 2-bromopropionate, ethyl 3-
bromobutyrate, or ethyl 4-(bromomethyl)-
benzoate in the presence of anhyd. K2CO3 in 
dry N,N-dimethylformamide (DMF). Only 
the N1-endocyclic amino group of 
pyrazolopyrimidine reacted with bromo 
substituted analogues. Unprotected N4-
exocyclic amine was not reactive under this 
reaction condition as shown previously.9 
Ester hydrolysis with sodium hydroxide 
afforded the corresponding N1-substituted 
carboxylic acid derivatives of 3-
phenylpyrazolo[3,4-d]pyrimidine (8a-f, 
Scheme 2). All the synthesized compounds 
were characterized by NMR and mass 
spectroscopy.7  
N
N N
N
PhNH2
Z
N
N N
H
N
PhNH2
N
N N
N
PhNH2
Z
K2CO3, DMF
NaOH (3M)
BrCHZCO2Et
R
R
CO2Et CO2H
R
8c 9c/h :c/h
c. R = H, without Z
d. R = H, Z = CH2
e. R = H, Z = CH2CH2
f. R = CH3, without Z
g. R = CH3, Z =CH2
h. R = H, Z = 4-C6H4
 
Scheme 2. Synthesis of N1-carboxylic acid 
ester pyrazolo[3,4-d]pyrimidine derivatives. 
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3-Aryl substituted pyrazolo[3,4-
d]pyrimidine derivatives containing NH2, 
OH, NO2, and other functional groups at 
para and meta positions of the 3-phenyl 
group (10a-f) were synthesized using Suzuki 
reaction of 1-(cyclohexylmethyl)-3-iodo-
1H-pyrazolo-[3,4-d]pyrimidin-4-amine (9) 
with different boronic acid derivatives in the 
presence of Pd(PPh3)4 (Scheme 3).  
 
Scheme 3. Synthesis of 3-substituted 
pyrazolo[3,4-d]pyrimidine derivatives.  
 
Modification of NH2 group at C-4 position 
of pyrazolo[3,4-d]pyrimidine was achieved 
by the reaction of 6b with diethyl carbonate 
and bis(2-chloroethyl)carbonate to give 11a-
b (Scheme 4).  
 
Scheme 4. Synthesis of 4-amino substituted 
analogs of pyrazolo[3,4-d]pyrimidine. 
 
Synthesis of hydrazide derivative (12) was 
achieved by the reaction of 7a with 
hydrazine hydrate in DMF. Compound 12 
underwent reaction with 2H-pyran-2,4,6-
(3H,5H)-trione to afford 13 (Scheme 5).   
 
Scheme 5. Synthesis of hydrazide 
derivatives (12 and 13). 
The carboxylic acid derivatives (8a, 8b and 
8d) were used for the synthesis of the 
corresponding hydroxamates (15a-c) using 
solid-phase synthesis employing Fmoc-
based chemistry (Scheme 6). Fmoc-4-
nitrophenyl alanine was coupled with 
hydroxylamine Wang resin in the presence 
of HBTU and N-methylmorpholine (NMM) 
to yield polymer-bound hydroxamate 
derivative (14). The nitro group of 14 was 
reduced with SnCl2 and resulting amino 
group was coupled with 8a, 8b and 8d using 
HBTU as a coupling agent in NMM. The 
deprotection of the Fmoc group with 20% 
piperidine in DMF followed by treatment 
with TFA afforded 15a-c. 
 
Scheme 6. Synthesis of hydroxamate 
derivatives of 3-phenylpyrazolopyrimidine. 
 
Tyrosine Kinase Inhibitory Activity. 
Protein tyrosine kinase activities of all the 
compounds were determined by measuring 
phosphorylation of poly-E4Y (average MW: 
35kD) by the kinase using a standard 
radiometric PTK activity assay as described 
previously.10 The radioactive kinase assay 
was performed using active p60-c-Src 
(Upstate Cell Signaling, Cat. No. 14-117) 
and polyE4Y as an artificial substrate. The 
assays were done in duplicate and repeated 
at least three times. Control reactions 
lacking polyE4Y were included for each 
enzyme concentration to correct for any 
nonpolyE4Y-specific phosphorylation. The 
percentage of inhibition was plotted as a 
function of the compound. The 
concentration and IC50 values (the 
concentration of a compound that caused 
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50% inhibition) were obtained from such a 
plot. The inhibitory potencies of the 
synthesized compounds against active c-Src 
are given in Table 1.  
Table 1. Src kinase inhibitory activity. 
Comp. No. IC50 
(µM)a 
Comp. 
No. 
IC50 
(µM)a 
6a -b 8e 71 
Control (6b) 0.47 8f -b 
6c 6.2 10a 6.5 
6d 180 10b 260 
6e 5.6 10c 5.1 
7a 160 10d -b 
7b -b 10e 28 
7c 16 10f 56 
7d 11 11a 38 
7e 12 11b 690 
7f -b 12 275 
8a 250 13 280 
8b 220 15a 112 
8c 293 15b 46 
8d -b 15c 155 
aIC50 is the concentration required to 
produce 50% inhibition in the 
phosphorylation of polyE4Y by active c-Src 
(average of triplicate experiments). 
bNo inhibition was observed up to 500 µM. 
Compound 6b (IC50 = 0.47 µM), a close 
analog of PP1 lacking one methyl group, 
was used as a control and showed potent Src 
kinase inhibitory activity with an IC50 value 
of 0.47 µM. 3-Phenylpyrazolo[3,4-
d]pyrimidine derivatives substituted at N1 
endocyclic amine with a carboxylic acid 
(8a-f, 13), carboxylic acid esters (7a-f), and 
hydroxamate (15a-c) exhibited inhibitory 
potencies with IC50 values of 12 to >500 
µM. 3-Phenylpyrazolopyrimidine derivative 
8a substituted with an alkyl carboxylic acid 
at N1-endocyclic amine, exhibited weak 
inhibitory potency (IC50 = 250 µM). A 
similar pattern was observed by the 
attachment of alkyl carboxylic acids 
containing a longer alkyl chain, as shown in 
8b-d and 8f.  
Molecular modeling studies indicate that the 
carboxylic acids in these compounds have 
unfavorable electrostatic interaction with the 
side chain of Asp386 (Figure 2). This 
residue is in the proximity of the cavity 
occupied by the ATP binding site inhibitors. 
When the methyl group was incorporated on 
the β-carbon of the side chain of alkyl 
carboxylic acid in 8e, a higher inhibitory 
potency (IC50 = 71 µM) was resulted (8e 
versus 8b); this may be due to the enhanced 
hydrophobic interaction by the methyl group 
with the hydrophobic cavity. Inhibitory 
potency of the ethyl ester derivatives 7a and 
7c-e were improved slightly compared to 
their acid analogues 8a and 8c-e, suggesting 
that the short carboxylic acids as N1-
substituents have unfavorable electrostatic 
interaction with Asp386 that is reduced in 
ester conjugates. 
 
 
 
Figure 2. Binding of a 3-
phenylpyrazolopyrimidine to Src (1FMK) 
(10) and its proximity to aspartic acids 
located in the kinase domain. 
 
Among 3-substituted pyrazolo[3,4-
d]pyrimidine derivatives, 3-(3′-
hydroxyphenyl)-N1-methylcyclohexyl 
pyrazolo[3,4-d]pyrimidine (10c) exhibited 
significantly improved inhibitory potency 
(IC50 = 5.1 µM). Similarly 3-phenyl-N1-
cyclohexyl derivative 6e exhibited inhibition 
of Src kinase with an IC50 value of 5.6 µM. 
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These results indicate that the introduction 
of a hydrophobic group at N1-position and a 
small functional group on the phenyl ring 
capable of hydrogen bonding, such as OH, 
as shown in compounds 6e and 10c, 
respectively, improve the inhibitory potency 
for c-Src kinase. This may be due to the 
rigid structure of cyclohexyl group in 6e that 
fits well in the hydrophobic pocket of c-Src.  
Structure-activity relationship studies 
suggested that the incorporation of bulky 
groups at N1 and N4-amino groups are not 
tolerated as shown in compounds 15a-c and 
11a-b. It has been previously reported that 
tethering bulky chemical groups to PP1 
through its exocyclic amine (N4) yields 
weak inhibitors11, owing to the unfavorable 
interactions12 with a structurally conserved 
amino acid residue 338 that contains a bulky 
side chain in all known eukaryotic protein 
kinases. Substitution at N4 in 3-phenyl-
pyrazolopyrimidine derivatives with esters 
or larger groups in 11a and 11b significantly 
reduced the inhibitory potency, therefore 
confirming the previous results. 
 
We have previously shown that 
hydroxamates can act as metal-mediated 
inhibitors of Csk.13 Thus, we evaluated 
hydroxamate compounds 15a, 15b and 15c 
for inhibition of human Csk. To determine 
the inhibition of Csk by hydroxamate 
compounds, 0.2 mM CoCl2 was also added 
to the reaction mixture. It was found that 
15a, 15b, and 15c act as potent metal-
mediated inhibitors with IC50 values of 2.0, 
2.7 and 5.0 µM, respectively. Thus, 
conjugating hydroxamate on the phenyl ring 
in 15a-c enhanced the inhibitory potency 
approximately 2- to 4.75-fold higher when 
compared to tyrosine hydroxamate (IC50 = 
9.5 µM). Moreover, while compound 15a 
was a poor inhibitor of c-Src kinase (IC50 
=112 µM), it showed 56-fold selectivity 
towards Csk (IC50 = 2.0 µM) in the presence 
of CoCl2. These compounds can be further 
optimized to develop selective inhibitors of 
Csk. 
 
Conclusions 
 
In conclusion, we have synthesized a series 
of pyrazolo[3,4-d]pyrimidine derivatives 
and evaluated them for the c-Src kinase 
inhibitory activities. Among all the 
compounds, 6b (IC50 = 0.47 µM) was the 
most potent derivative. Compounds 6e, 10a, 
and 10c exhibited modest inhibition of Src 
kinase with IC50 values of 5.1-6.5 µM, 
respectively. Structure-activity relationship 
studies suggested that the incorporation of 
bulky groups at N1 and N4-amino groups 
were not tolerated. The data provides insight 
for further optimization of these compounds 
by incorporation of smaller hydrophobic 
groups at N1 or hydrophobic aryl groups 
with hydrogen bonding substituents at C3-
position of pyrazolopyrimidine scaffold. 
Hydroxamate derivatives of pyrazolo[3,4-
d]pyrimidine were found to be selective 
inhibitors of Csk. Taken together, these 
results suggest that further exploration and 
optimization of functional groups and their 
positioning in pyrazolo[3,4-d]pyrimidine 
derivatives could lead to more potent Src 
inhibitors. 
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